Literature DB >> 15220758

Management of chylothorax via percutaneous embolization.

Constantin Cope1.   

Abstract

PURPOSE OF REVIEW: The purpose of this review is to present a novel radiologic percutaneous transabdominal technique for treating high-output chylothorax by thoracic duct embolization, and to demonstrate that it can be potentially safer than the traditional treatment by surgical open-chest thoracic duct ligation. RECENT
FINDINGS: Pedal lymphography is initially performed to opacify large retroperitoneal lymph channels; a suitable duct more than 2 mm in diameter is then punctured transabdominally to allow catheterization and embolization of the thoracic duct under fluoroscopic guidance. If feeding lymphatic channels are too small for catheterization, they can often be occluded by needle disruption. This percutaneous interventional technique, which has been used in 60 patients with mostly high-output chylothorax caused by thoracic surgery, resulted in a 65% cure rate with no morbidity. Back-up surgical thoracic duct ligation was performed promptly on suitable lower risk patients when the percutaneous procedure failed.
SUMMARY: We have found that two thirds of patients presenting with life-threatening chylothorax can be safely treated by percutaneous transabdominal thoracic duct blockage. When successful, this novel interventional procedure can obviate repeat major thoracic surgery and shorten hospital stays.

Entities:  

Mesh:

Year:  2004        PMID: 15220758     DOI: 10.1097/01.mcp.0000127903.45446.6d

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  10 in total

1.  Blood patch treatment of chylothorax following transthoracic oesophagogastrectomy: a novel technique to aid surgical management.

Authors:  R A J Windhaber; A G Holbrook; R J Krysztopik
Journal:  Ann R Coll Surg Engl       Date:  2010-05       Impact factor: 1.891

Review 2.  The thoracic duct: clinical importance, anatomic variation, imaging, and embolization.

Authors:  Oren W Johnson; Jeffrey Forris Beecham Chick; Nikunj Rashmikant Chauhan; Alexandra Holmsen Fairchild; Chieh-Min Fan; Michael S Stecker; Timothy P Killoran; Alisa Suzuki-Han
Journal:  Eur Radiol       Date:  2015-12-01       Impact factor: 5.315

3.  A staged management of prolonged chylothorax in a patient with yellow nail syndrome.

Authors:  James Tidder; Chun Lap Pang
Journal:  BMJ Case Rep       Date:  2012-11-01

4.  Octreotide for conservative management of intractable high output post operative chylous fistula: a case report.

Authors:  Sundararaman Prabhu; Shaji Thomas
Journal:  J Maxillofac Oral Surg       Date:  2011-08-05

Review 5.  Role of Interventional Radiology in the Management of Non-aortic Thoracic Trauma.

Authors:  Mikhail C S S Higgins; Jessica Shi; Mohammad Bader; Paul A Kohanteb; Tejal S Brahmbhatt
Journal:  Semin Intervent Radiol       Date:  2022-08-31       Impact factor: 1.780

6.  Pleural fluid characteristics of chylothorax.

Authors:  Fabien Maldonado; Finn J Hawkins; Craig E Daniels; Clinton H Doerr; Paul A Decker; Jay H Ryu
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

7.  Pleural effusions in children undergoing cardiac surgery.

Authors:  Sachin Talwar; Sandeep Agarwala; Chander Mohan Mittal; Shiv Kumar Choudhary; Balram Airan
Journal:  Ann Pediatr Cardiol       Date:  2010-01

8.  A rare case of chylothorax in a patient with schimmelpenning syndrome.

Authors:  Bettina Schlolaut; Hans Heinz Schild; Joachim Pfannschmidt; Dirk Kaiser
Journal:  Thorac Cardiovasc Surg Rep       Date:  2014-10-31

9.  Iatrogenic Thoracic Duct Injury via the Right Internal Jugular Vein: A Case Report.

Authors:  Hiroki Kono; Daiki Shako; Yoshimi Sato; Tatsuya Kawasaki
Journal:  J Med Cases       Date:  2022-06-11

10.  Radiotherapy in the treatment of postoperative chylothorax.

Authors:  Zsolt Sziklavari; Michael Allgäuer; Georg Hübner; Reiner Neu; Michael Ried; Christian Grosser; Tamas Szöke; Rudolf Schemm; Hans-Stefan Hofmann
Journal:  J Cardiothorac Surg       Date:  2013-04-08       Impact factor: 1.637

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.